Clinical trials are clinical research studies conducted to investigate new treatments such as a new drug compound in human volunteers or research participants. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses.

Such research takes a cautious and progress in a sequential or phase approach. Research is conducted into new medications or therapeutic
goods but can also involve products that are already available on the market, for further improvement.

Clinical trials offer hope for many people and an opportunity to help researchers find better treatments for others in the future.

Clinical Trials

Different phases of trial:

A phase of research to describe clinical trials that focus on the safety of a drug. They are usually conducted with healthy volunteers, and the goal is to determine the drug’s most frequent and serious adverse events and, often, how the drug is broken down and excreted by the body. These trials usually involve a small number of participants.

A phase of research to describe clinical trials that gather preliminary data on whether a drug works in people who have a certain condition/disease (that is, the drug’s effectiveness). For example, participants receiving the drug may be compared to similar participants receiving a different treatment, usually an inactive substance (called a placebo) or a different drug. Safety continues to be evaluated, and short-term adverse events are studied.

A phase of research to describe clinical trials that gather more information about a drug’s safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs. These studies typically involve more participants.

A phase of research to describe clinical trials occurring after FDA has approved a drug for marketing. They include postmarket requirement and commitment studies that are required of or agreed to by the study sponsor. These trials gather additional information about a drug’s safety, efficacy, or optimal use.

Study DescriptionProtocol NumberPhaseTherapeutic AreaIndicationSponsor
First-In-Man Feasibility Study for a Zone V Flexor Tendon Repair DeviceCTR-FIM-SG-001FIMOrthopaedic SurgeryZone V Flexor Tendon InjuryCapere Surgical Systems
First-in-Human Study to Evaluate the Safety and Efficacy of PAKHD in ESRD PatientsPAKHD2FIMNephrologyEnd-stage renal disease (ESRD)Nextkidney SG Pte Ltd
Medical device study on treatment of Benign Prostatic Hyperplasia using ProstaCare Water Electrolysis SystemPC 1.0Medical DeviceUrologyBenign Prostatic HyperplasiaProstaCare
Clinical Evaluation Protocol of External Access Targeting DeviceINVIVO-CEP-01Medical DeviceUrologyPercutaneous renal stoneInvivo Medical Pte Ltd
Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of a Single Ascending Dose (SAD) of CAN106 Administered Intravenously (IV) in Healthy SubjectsCAN106IHaematologyParoxysmal Nocturnal Hemoglobinuria (PNH)CARE Pharma Shanghai Ltd
A Phase I, Open-label Study to determine Safety and Tolerability of the Topical Application of Mesenchymal Stem/Stromal Cell (MSC) Exosome Ointment to Treat Psoriasis in Healthy VolunteersPTD2021P001IDermatologyPsoriasisParacrine Therapeutics Dermatology Pte Ltd
A Phase 1b, Multicenter, Open-Label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of Mezagitamab (TAK-079) in Patients With Primary IgA Nephropathy in Combination With Stable Background TherapyTAK-079IbNephrologyPrimary IgA NephropathyTakeda Development Center Americas, Inc
A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in adult acute leukemia patients with and without mixed lineage Leukemia Rearrangement or Nucleophosmin 1 MutationDSP-5336I/IIHaematologyAcute LeukemiaSumitomo Pharma Oncology, INC
A Phase I/III Randomized, Double-blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156/AZD3152 for Pre-exposure Prophylaxis of COVID-19 in Participants with Conditions Causing Immune ImpairmentD7000C00001I/IIIInfectious DiseasesPre-exposure Prophylaxis of COVID-19 with Immune ImpairmentAstraZeneca AB
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgeryCTIN816A12201IINephrology/CardiologyAcute kidney injuryNovartis (Singapore) Pte Ltd
Controlled Study of Immunogenicity and safety of the Investigational vYF candidate vaccine in comparison to Stamaril in AdultsVYF03IIInfectious DiseasesYellow feverSanofi-Aventis Singapore Pte Ltd
Randomised, double-blind, placebo-controlled, Phase IIb/Phase III study to evaluate the efficacy and safety of spesolimab in patients with moderate to severe hidradenitis suppurativa (BI-1368-0098)BI-1368-0098IIDermatologyHidradenitis suppurativaBoehringer Ingelheim Singapore Pte. Ltd
Phase 2 Autism study to assess long-term efficacy of Intranasal Oxytocin and the underlying neural mechanisms1.0IIPsychologyAutismN/A
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) NephropathyVIS649IINephrologyPrimary IgA NephropathyVisterra, Inc.
A randomized, treatment open-label, dose-blinded parallel group, three arm, proof-of-concept clinical trial to investigate the efficacy and safety of LNP023 compared with rituximab in the treatment of subjects with idiopathic membranous nephropathyCLNP023D12201IINephrologyIdiopathic membranous nephropathyNovartis (Singapore) Pte Ltd
A Phase 2/3 Randomized, Placebo-Controlled, Double-blind, Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants with Heart Failure due to Systemic Left Ventricular Systolic Dysfunction (VALOR)036-00II/IIICardiologyHeart failureMerck Sharp & Dohme LLC
A Phase III: randomized, sham-controlled, double-blind trial to evaluate the efficacy and safety of intrathecal (IT) OAV101, single dose (1.2E4vg) in later onset type 2 SMA age > 2 to <18 years of age, treatment naïve, sitting and never ambulatory (COAV101B12301)COAV101B12301IIIPaediatricType 2 SMANovartis (Singapore) Pte Ltd
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy, safety, and tolerability of remibrutinib (LOU064) in chronic inducible urticaria (CINDU) in adults in inadequately controlled by H1-antihistaminesCLOU064M12301IIIDermatologyChronic inducible urticariaNovartis (Singapore) Pte Ltd
A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily iptacopan in adult PNH patients who are naïve to complement inhibitor therapyCLNP023C12301IIIHaematologyParoxysmal Nocturnal Hemoglobinuria (PNH)Novartis (Singapore) Pte Ltd
Phase 3 Allergy study to investigate the effect of a partially hydrolysed infant formula with added synbiotics (Maestro)EBB15BL89859IIIOthersAllergyNutricia Research
A Phase 3 randomized controlled study of REACT in participants with Type 2 DiabetesREGEN-016IIINephrologyType 2 DiabetesProKidney Corp
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial HypercholesterolemiaMK-0616-017-00 IIIEndocrinologyHeterozygous Familial HypercholesterolemiaMerck Sharp & Dohme LLC
AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF POZELIMAB AND CEMDISIRAN COMBINATION THERAPY IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIAR3918-PNH-2050IIIHaematologyParoxysmal Nocturnal Hemoglobinuria (PNH)Regeneron Pharmaceuticals, Inc.
Phase 3 Anemia Study in CKD to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa (ASCEND-ND)GSK1278863IIINephrologyAnemiaGlaxoSmithKline
Phase 3 Anemia Study in CKD to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin (ASCEND-D)GSK1278863IIINephrologyAnemiaGlaxoSmithKline
Phase 3 haematology study to evaluate the safety and efficacy of ALXN1210 compared to eculizumabALXN1210-PNH-301IIIHaematologyParoxysmal Nocturnal Hemoglobinuria (PNH)Alexion Pharmaceuticals, Inc
Phase 3 Venous Thromboembolism study to evaluate the efficacy and safety of an age and body weight adjusted rivaroxaban regimenBAY14372IIICardiovascularVenous ThromboembolismBayer
An open-label, multicentre, single-arm, post-marketing trial to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab i.v. in treatment of patients with Generalized Pustular Psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab i.vBI1368-0120IIIb/IVDermatologyGeneralized Pustular PsoriasisBoehringer Ingelheim Singapore Pte Ltd
Phase 4 Adverse Drug Reaction study on serious skin rashHSARF-SSR-P01IVDermatologySerious Adverse Reaction suspected to be related to a drugHealth Science Authority
Phase 4 Dengue study - KETODENEID-DF-02IVInfectious DiseaseDengueN/A
Top